Cooley, Mintz Levin Craft $3.05B Deal For Drug Developer
Horizon Therapeutics, advised by Cooley, has agreed to acquire Mintz Levin-counseled Viela Bio for roughly $3.05 billion, the companies said Monday, in a deal that serves to strengthen the buyer's ability...To view the full article, register now.
Already a subscriber? Click here to view full article